For AbbVie, the good news this week is that the failure of a high-profile schizophrenia drug in two key trials hardly marks its last opportunity to make strides in neuroscience. The bad news is that the effort might not get any easier.
The company has had high hopes for the schizophrenia treatment, called emraclidine, which was the centerpiece of its $9 billion acquisition of Cerevel Therapeutics. Those hopes dimmed Monday after two Phase 2 trials showed that patients on the treatment experienced no significant improvement compared to those on placebo.
But the company indicated that it’s not ready to give up on emraclidine yet — and it has other neuroscience drugs in its pipeline that could show potential soon.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
